The growth hormone hypothesis - 2005 Revision

Hormone and Metabolic Research

Volumn 37, Issue SUPPL. 1, 2005, Pages

  Frystyk, J ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

GH; GH hypothesis; IGF I; Pegvisomant; Proliferative diabetic retinopathy; Somatostatin analogues

Indexed keywords

GROWTH HORMONE; SOMATOMEDIN C;

CLINICAL RESEARCH; CONFERENCE PAPER; DIABETIC RETINOPATHY; EXPERIMENTAL MEDICINE; HUMAN; HYPOTHESIS; MEDICAL LITERATURE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL;

ANIMALS; DIABETIC RETINOPATHY; HUMAN GROWTH HORMONE; HUMANS; INSULIN-LIKE GROWTH FACTOR I;

EID: 20444454294     PISSN: 00185043     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2005-861362     Document Type: Conference Paper

References (64)

1. Frank RN. Diabetic retinopathy. N Engl J Med 2004; 350: 48-58
2. Lundbæk K, Jensen VA, Olsen TS, Ørskov H, Christensen NJ, Johansen K, Hansen AP, Østerby R. Diabetes, diabetic angiopathy, and growth hormone. Lancet 1970; 2 :131-133
3. Poulsen JE. Recovery from retinopathy in a case of diabetes with Simmonds' disease. Diabetes 1953; 2: 7-12
4. Ørskov H, Thomsen HG, Yde H. Wick chromatography for rapid and reliable immunoassay of insulin, glucagon and growth hormone. Nature 1968; 219: 193-195
5. Luft R, Olivecrona H, Ikkos D, Kornerup T, Ljunggren H. Hypophysectomy in man; further experiences in severe diabetes mellitus. Br Med J 1955; 24: 752-756
6. Sharp PS, Fallon TJ, Brazier OJ, Sandler L, Joplin GF, Kohner EM. Long-term follow-up of patients who underwent yttrium-90 pituitary implantation for treatment of proliferative diabetic retinopathy. Diabetologia 1987; 30: 199-207
7. Wright AD, Kohner EM, Oakley NW, Hartog M, Joplin GF, Fraser TR. Serum growth hormone levels and the response of diabetic retinopathy to pituitary ablation. Br Med J 1969; 2: 346-348
8. Das A, McGuire PG. Retinal and choroidal angiogenesis: pathophysiology and strategies for inhibition. Prog Retin Eye Res 2003; 22: 721-748
9. Rymaszewski Z, Cohen RM, Chomczynski P. Human growth hormone stimulates proliferation of human retinal microvascular endothelial cells in vitro. Proc Natl Acad Sci USA 1991; 88: 617-621
10. Grant MB, Guay C, Marsh R. Insulin-like growth factor I stimulates proliferation, migration, and plasminogen activator release by human retinal pigment epithelial cells. Curr Eye Res 1990; 9: 323-335
11. Spoerri PE, Ellis EA, Tarnuzzer RW, Grant MB. Insulin-like growth factor: receptor and binding proteins in human retinal endothelial cell cultures of diabetic and non-diabetic origin. Growth Horm IGF Res 1998; 8: 125-132
12. Smith LE, Kopchick JJ, Chen W, Knapp J, Kinose F, Daley D, Foley E, Smith RG, Schaeffer JM. Essential role of growth hormone in ischemia-induced retinal neovascularization. Science 1997; 276: 1706-1709
13. Poulaki V, Joussen AM, Mitsiades N, Mitsiades CS, Iliaki EF, Adamis AP. Insulin-like growth factor I plays a pathogenetic role in diabetic retinopathy. Am J Pathol 2004; 165: 457-469
14. Smith LE, Shen W, Perruzzi C, Soker S, Kinose F, Xu X, Robinson G, Driver S, Bischoff J, Zhang B, Schaeffer JM, Senger DR. Regulation of vascular endothelial growth factor-dependent retinal neovascularization by insulin-like growth factor I receptor. Nat Med 1999; 5: 1390-1395
15. Poulaki V, Qin W, Joussen AM, Hurlbut P, Wiegand SJ, Rudge J, Yancopoulos GD, Adamis AP. Acute intensive insulin therapy exacerbates diabetic blood-retinal barrier breakdown via hypoxia-inducible factor-1 alpha and VEGF. J Clin Invest 2002; 109: 805-815
16. Chantelau E, Eggert H, Seppel T, Schonau E, Althaus C. Elevation of serum IGF-1 precedes proliferative diabetic retinopathy in Mauriac's syndrome [letter]. Br J Ophthalmol 1997; 81: 169-170
17. Hyer SL, Sharp PS, Sleightholm M, Burrin JM, Kohner EM. Progression of diabetic retinopathy and changes in serum insulin-like growth factor I (IGF-I) during continuous subcutaneous insulin infusion (CSII). Horm Metab Res 1989; 21: 18-22
18. Grant M, Russell B, Fitzgerald C, Merimee TJ. Insulin-like growth factors in vitreous. Studies in control and diabetic subjects with neovascularization. Diabetes 1986; 35: 416-420
19. Burgos R, Mateo C, Canton A, Hernandez C, Mesa J, Simo R. Vitreous levels of IGF-I, IGF binding protein 1, and IGF binding protein 3 in proliferative diabetic retinopathy: a case-control study. Diabetes Care 2000; 23: 80-83
20. Meyer Schwickerath R, Pfeiffer A, Blum WF, Freyberger H, Klein M, Losche C, Rollmann R, Schatz H. Vitreous levels of the insulin-like growth factors I and II, and the insulin-like growth factor binding proteins 2 and 3, increase in neovascular eye disease. Studies in nondiabetic and diabetic subjects. J Clin Invest 1993; 92: 2620-2625
21. Spranger J, Buhnen J, Jansen V, Krieg M, Meyer-Schwickerath R, Blum WF, Schatz H, Pfeiffer AF. Systemic levels contribute significantly to increased intraocular IGF-I, IGF-II and IGF-BP3 in proliferative diabetic retinopathy. Horm Metab Res 2000; 32: 196-200
22. Waldbillig RJ, Jones BE, Schoen TJ, Moshayedi P, Heidersbach S, Bitar MS, van Kuijk FJ, de Juan E, Kador P, Chader GJ. Vitreal insulin-like growth factor binding proteins (IGFBPs) are increased in human and animal diabetics. Curr Eye Res 1994; 13: 539-546
23. Boulton M, Gregor Z, McLeod D, Charteris D, Jarvis Evans J, Moriarty P, Khaliq A, Foreman D, Allamby D, Bardsley B. Intravitreal growth factors in proliferative diabetic retinopathy: correlation with neovascular activity and glycaemic management. Br J Ophthalmol 1997; 81: 228-233
24. Hopkins KD, Brart DO, Russell Jones DL, Chignell AH, Sönksen PH. Insulin-like growth factor binding protein-1 levels in diabetic proliferative retinopathy. Horm Metab Res 1993; 25: 331-332
25. Arnold DR, Moshayedi P, Schoen TJ, Jones BE, Chader GJ, Waldbillig RJ. Distribution of IGF-I and -II, IGF binding proteins (IGFBPs) and IGFBP mRNA in ocular fluids and tissues: potential sites of synthesis of IGFBPs in aqueous and vitreous. Exp Eye Res 1993; 56: 555-565
26. Pfeiffer A, Spranger J, Meyer-Schwickerath R, Schatz H. Growth factor alterations in advanced diabetic retinopathy: a possible role of blood retina barrier breakdown. Diabetes 1997; 46 Suppl 2: S26-S30
27. Hyer SL, Sharp PS, Brooks RA, Burrin JM, Kohner EM. A two-year follow-up study of serum insulin like growth factor-I in diabetics with retinopathy. Metabolism 1989; 38: 586-589
28. Acerini CL, Patton CM, Savage MO, Kernell A, Westphal O, Dunger DB. Randomised placebo-controlled trial of human recombinant insulin-like growth factor I plus intensive insulin therapy in adolescents with insulin-dependent diabetes mellitus. Lancet 1997; 350: 1199-1204
29. Lauszus FF, Klebe JG, Bek T, Flyvbjerg A. Increased serum IGF-I during pregnancy is associated with progression of diabetic retinopathy. Diabetes 2003; 52: 852-856
30. Grant MB, Caballero S. Somatostatin analogues as drug therapies for retinopathies. Drugs Today (Barc) 2002; 38: 783-791
31. Kopchick JJ, Parkinson C, Stevens EC, Trainer PJ. Growth hormone receptor antagonists: discovery, development, and use in patients with acromegaly. Endocr Rev 2002; 23: 623-646
32. Grant MB, Caballero S, Millard WJ. Inhibition of IGF-I and b-FGF stimulated growth of human retinal endothelial cells by the somatostatin analogue, octreotide: a potential treatment for ocular neovascularization. Regul Pept 1993; 48: 267-278
33. Hyer SL, Sharp PS, Brooks RA, Burrin JM, Kohner EM. Continuous subcutaneous octreotide infusion markedly suppresses IGF-I levels whilst only partially suppressing GH secretion in diabetics with retinopathy. Acta Endocrinol (Copenh) 1989; 120: 187-194
34. Kirkegaard C, Nørgaard K, Snorgaard O, Bek T, Larsen M, Lund-Andersen H. Effect of one year continuous subcutaneous infusion of a somatostatin analogue, octreotide, on early retinopathy, metabolic control and thyroid function in Type 1 (insulin-dependent) diabetes mellitus. Acta Endocrinol (Copenh) 1990; 122: 766-772
35. Shumak SL, Grossman LD, Chew E, Kozousek V, George SR, Singer W, Harris AG, Zinman B. Growth hormone suppression and nonproliferative diabetic retinopathy: a preliminary feasibility study. Clin Invest Med 1990; 13: 287-292
36. McCombe M, Lightman S, Eckland DJ, Hamilton AM, Lightman SL. Effect of a long-acting somatostatin analogue (BIM23014) on proliferative diabetic retinopathy: a pilot study. Eye 1991; 5 (Pt 5): 569-575
37. Mallet B, Vialettes B, Haroche S, Escoffier P, Gastaut P, Taubert JP, Vague P. Stabilization of severe proliferative diabetic retinopathy by long-term treatment with SMS 201-995. Diabete Metab 1992; 18: 438-444
38. Boehm BO, Lang GK, Jehle PM, Feldman B, Lang GE. Octreotide reduces vitreous hemorrhage and loss of visual acuity risk in patients with high-risk proliferative diabetic retinopathy. Horm Metab Res 2001; 33: 300-306
39. Grant MB, Mames RN, Fitzgerald C, Hazariwala KM, Cooper-DeHoff R, Caballero S, Estes KS. The efficacy of octreotide in the therapy of severe nonproliferative and early proliferative diabetic retinopathy: a randomized controlled study. Diabetes Care 2000; 23: 504-509
40. Growth Hormone Antagonist for Proliferative Diabetic Retinopathy Study Group. The effect of a growth hormone receptor antagonist drug on proliferative diabetic retinopathy. Ophthalmology 2001; 108: 2266-2272
41. Holt RI, Simpson HL, Sönksen PH. The role of the growth hormone-insulin-like growth factor axis in glucose homeostasis. Diabet Med 2003; 20: 3-15
42. Powell ED, Frantz AG, Rabkin MT, Field RA. Growth hormone in relation to diabetic retinopathy. N Engl J Med 1966; 275: 922-925
43. Buckle JF, Schlienger JL, de Laharpe F, Stephan F. Growth hormone response to thyrotropin-releasing hormone in insulin-dependent diabetics with or without severe microvascular lesions. Diabete Metab 1982; 8: 197-201
44. Sharp PS, Foley K, Vitelli F, Maneschi F, Kohner EM. Growth hormone response to hyperinsulinaemia in insulin-dependent diabetics. Comparison of patients with and without retinopathy. Diabet Med 1984; 1: 55-58
45. Kaneko K, Komine S, Maeda T, Ohta M, Tsushima T, Shizume K. Growth hormone responses to growth-hormone-releasing hormone and thyrotropin-releasing hormone in diabetic patients with and without retinopathy. Diabetes 1985; 34: 710-713
46. Almqvist EG, Groop LC, Manhem PJ. Growth hormone response to the insulin tolerance and clonidine tests in type 1 diabetes. Scand J Clin Lab Invest 1999; 59: 375-382
47. Savage MO, Camacho-Hubner C, Dunger DB. Therapeutic applications of the insulin-like growth factors. Growth Horm IGF Res 2004; 14: 301-308
48. Frystyk J. Free insulin-like growth factors-measurements and relationships to growth hormone secretion and glucose homeostasis. Growth Horm IGF Res 2004; 14: 337-375
49. Johansen K, Hansen AaP. Diurnal serum growth hormone levels in poorly and well controlled juvenile diabetics. Diabetes 1971; 20: 239-245
50. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. N Engl J Med 2000; 342: 381-389
51. Kjeldsen H, Hansen AP, Lundbæk K. Twenty-four-hour serum growth hormone levels in maturity-onset diabetics. Diabetes 1975; 24: 977-982
52. Scacchi M, Pincelli AI, Cavagnini F. Growth hormone in obesity. Int J Obes Relat Metab Disord 1999; 23: 260-271
53. Lindström T, Nyström FH, Olsson AG, Ottosson A-M, Arnqvist HJ. The lipoprotein profile differs during insulin treatment alone and combination therapy with insulin and sulphonylureas in patients with Type 2 diabetes mellitus. Diabetic Medicine 1999; 16: 820-826
54. Gibson JM, Westwood M, Crosby SR, Gordon C, Holly JM, Fraser W, Anderson C, White A, Young RJ. Choice of treatment affects plasma levels of insulin-like growth factor-binding protein-1 in noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab 1995; 80: 1369-1375
55. Clauson PG, Brismar K, Hall K, Linnarsson R, Grill V. Insulin-like growth factor I and insulin-like growth factor binding protein-1 in a representative population of type 2 diabetic patients in Sweden. Scand J Clin Lab Invest 1998; 58: 353-360
56. Frystyk J, Ivarsen P, Skjærbæk C, Flyvbjerg A, Pedersen EB, Ørskov H. Serum-free insulin-like growth factor I correlates with clearance in patients with chronic renal failure. Kidney Int 1999; 56: 2076-2084
57. Dills DG, Moss SE, Klein R, Klein BE, Davis M. Is insulin-like growth factor I associated with diabetic retinopathy? Diabetes 1990; 39: 191-195
58. Feldmann B, Jehle PM, Mohan S, Lang GE, Lang GK, Brueckel J, Boehm BO. Diabetic retinopathy is associated with decreased serum levels of free IGF-I and changes of IGF-binding proteins. Growth Horm IGF Res 2000; 10: 53-59
59. Frystyk J, Bek T, Flyvbjerg A, Skjærbæk C, Ørskov H. The relationship between the circulating IGF system and the presence of retinopathy in Type 1 diabetic patients. Diabet Med 2003; 20: 269-276
60. Hyer SL, Sharp PS, Brooks RA, Burrin JM, Kohner EM. Serum IGF-1 concentration in diabetic retinopathy. Diabet Med 1988; 5: 356-360
61. Janssen JA, Jacobs ML, Derkx FH, Weber RF, van der Lely AJ, Lamberts SW. Free and total insulin-like growth factor I (IGF-I), IGF-binding protein-1 (IGFBP-1), and IGFBP-3 and their relationships to the presence of diabetic retinopathy and glomerular hyperfiltration in insulin-dependent diabetes mellitus. J Clin Endocrinol Metab 1997; 82: 2809-2815
62. Merimee TJ, Zapf J, Froesch ER. Insulin-like growth factors. Studies in diabetics with and without retinopathy. N Engl J Med 1983; 309: 527-530
63. Wang Q, Dills DG, Klein R, Klein BE, Moss SE. Does insulin-like growth factor I predict incidence and progression of diabetic retinopathy? Diabetes 1995; 44: 161-164
64. Frystyk J, Skjærbæk C, Vestbo E, Fisker S, Ørskov H. Circulating levels of free insulin-like growth factors in obese subjects: the impact of type 2 diabetes. Diabetes Metab Res Rev 1999; 15: 314-322